OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
June 11, 2024
A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.
June 09, 2024
Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.
June 05, 2024
Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.
Webinar Date/Time: Thu, Jun 27, 2024 11:00 AM EDT
June 04, 2024
Webinar Date/Time: Thursday, June 20, 2024 - 11am EDT | 4pm GMT | 5pm CEST
June 03, 2024
Webinar Date/Time: Thu, Jun 20, 2024 11:00 AM EDT
May 30, 2024
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.